Abbott Laboratories
ABT
$105.90
-$0.02-0.02%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 5.72B | 5.16B | 5.16B | 5.80B | 6.93B |
| Total Depreciation and Amortization | 3.24B | 3.24B | 3.23B | 3.25B | 3.27B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 770.00M | 860.00M | 866.00M | 876.00M | 900.00M |
| Change in Net Operating Assets | -2.48B | -2.71B | -1.80B | -1.27B | -1.52B |
| Cash from Operations | 7.26B | 6.55B | 7.45B | 8.66B | 9.58B |
| Capital Expenditure | -2.20B | -2.06B | -1.96B | -1.84B | -1.78B |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -877.00M | -877.00M | -826.00M | -- | -- |
| Divestitures | 40.00M | 40.00M | 40.00M | 48.00M | 48.00M |
| Other Investing Activities | -94.00M | -47.00M | -41.00M | -54.00M | -11.00M |
| Cash from Investing | -3.13B | -2.94B | -2.79B | -1.84B | -1.74B |
| Total Debt Issued | 23.00M | 11.00M | 36.00M | 46.00M | 54.00M |
| Total Debt Repaid | -2.50B | -1.54B | -32.00M | -44.00M | -753.00M |
| Issuance of Common Stock | 167.00M | 174.00M | 175.00M | 170.00M | 167.00M |
| Repurchase of Common Stock | -1.23B | -1.65B | -2.45B | -2.03B | -3.80B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -3.56B | -3.49B | -3.43B | -3.37B | -3.31B |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -7.09B | -6.50B | -5.70B | -5.22B | -7.64B |
| Foreign Exchange rate Adjustments | -23.00M | 3.00M | -64.00M | -108.00M | -122.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.99B | -2.89B | -1.10B | 1.49B | 83.00M |
